Lixte Biotechnology Holdings Inc (LIXT)

NASDAQ
2.090
+0.019(+0.94%)
  • Volume:
    28,059
  • Bid/Ask:
    2.090/2.100
  • Day's Range:
    2.055 - 2.100

LIXT Overview

Prev. Close
2.07
Day's Range
2.055-2.1
Revenue
-
Open
2.1
52 wk Range
1.97-7.19
EPS
-0.48
Volume
28,059
Market Cap
28.46M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
390,943
P/E Ratio
-
Beta
-1.28
1-Year Change
-70.76%
Shares Outstanding
13,746,593
Next Earnings Date
-
What is your sentiment on Lixte Biotechnology Holdings Inc?
or
Vote to see community's results!

Lixte Biotechnology Holdings Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyBuyStrong SellStrong Sell

Lixte Biotechnology Holdings Inc Company Profile

Lixte Biotechnology Holdings Inc Company Profile

Employees
3

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher’s disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and study with the National Cancer Institute. The company was founded in 2005 and is based in East Setauket, New York.

Read More
  • Moving on up $3.15
    0
    • All these biotech stocks have strong buys then they sell off a week later
      1
      • that's bio tech for ya...
        1
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.